Vitamin K2 changed bone markers; clinical benefits remain unconfirmed
In postmenopausal osteoporosis studies, supplementation altered several laboratory markers. The abstract does not establish stronger bones or fewer fractures.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Vitamin K2 supplementation changed several markers of bone turnover, including osteocalcin and its undercarboxylated form. Another marker, NTX, did not change significantly, and the clinical meaning of the small CTX reduction was uncertain. This is evidence about laboratory measurements in postmenopausal osteoporosis, with bone-density and fracture benefits still unconfirmed by the abstract.
The abstract does not provide comparator details, treatment duration, or units for the marker effects. It calls for longer-term studies to establish clinical benefits.
Different markers, different responses
The authors reported increases in osteocalcin and bone-specific alkaline phosphatase, alongside decreases in undercarboxylated osteocalcin and TRAP. The absence of a significant NTX change means the marker pattern was not uniform.
Measurements are not health outcomes
A change in a bone-turnover marker does not by itself show improved bone density or fracture prevention. The authors specifically identify confirmation of clinical benefits as a task for future studies.
The original publication
The effect of vitamin K2 supplementation on bone turnover biochemical markers in postmenopausal osteoporosis patients: a systematic review and meta-analysis.
Zhang Z, Li Y, Li J et al.
Front Endocrinol (Lausanne) · 2025
- PubMed ID
- 41268154
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.